Slide 1: Growing into a broader and stronger Orexo
ANNUAL GENERAL MEETING 2023 1 Growing into a broader and stronger Orexo
Slide 2: Legal disclaimer
2 Legal disclaimer • This presentation, which is personal to the recipient, has been prepared and produced by Orexo AB (publ) (“Orexo”) solely for the benefit of investment analysis and may not be used for any purpose other than assessment of investments concerning Orexo. Unless otherwise stated, Or
Slide 3: 2022 – advancing in a challenging environment
3 2022 – advancing in a challenging environment ▪ EU launch of ZUBSOLV® initiated by Accord Healthcare and ▪ ZUBSOLV® was added to NY Medicaid MAT Preferred Drug formulary ▪ R&D pipeline making strong progress ▪ OX124 ready for FDA filing ▪ Positive data from the 1st clinical study for OX640 ▪ Amorp
Slide 4: US Commercial
4 Business Update US Commercial 4
Slide 5: US market: Commercial products
5 US market: Opioid dependence Alcohol Depression management Commercial Overdose deaths surpassed 107 000 in 2021, fueled by use of 9m 17m 20m products synthetic opioids such as fentanyl are misusing opioids are heavy alcohol users are suffering from at least one targeting major depression annually
Slide 6: ZUBSOLV an important foundation to Orexo's commercial operations
6 ZUBSOLV® an important foundation to Orexo´s commercial operations Net revenues US Pharma EBIT (SEK m) and EBIT since launch 2013 Market dynamic margin (%) LTM 1 (SEK m) New legislation from Dec 28th 4,500 removing hurdles to prescribe 400 60,0% Bup/Nal products 350 50,0% Increased funding from $54
Slide 7: DTx comes with a lot of promise and potential, but yet to materialize
7 DTx comes with a lot of promise and potential, but yet to materialize MODIA® focusing on gaining acceptance in OUD clinics • >2000 patients received MODIA® in 2022 • Good progress in gaining reimbursement through medical benefits • MODIA® is included in the MATCore™ platform to be implemented in A
Slide 8: HQ & Pipeline
8 Business Update HQ & Pipeline 8
Slide 9: Orexo's development platform building on the proprietary amorphOX technology
9 Orexo´s development platform building on the proprietary amorphOX® technology Validated in humans Excellent stability Wide applicability ✓ Superior pharmacokinetic ✓ Excellent stability even under ✓ Powder technology that works with a broad scope of small and properties with more rapid onset, acce
Slide 10: amorphOX – a versatile, world-class platform for intranasal drug delivery
10 amorphOX® – a versatile, world-class platform for intranasal drug delivery Chemical degradation after accelerated stability studies at 40oC/75% RH Apomorphine Cetrorelix Eletriptan Olanzapine Enzyme Loxapine 0.3% after 18 months 0.4% after 3 months 0.5% after 3 months 0.3% after 6 months Ketorola
Slide 11: OX124 & OX125 – overdose rescue medications
11 OX124 & OX125 – overdose rescue medications Rescue drug market Global overdose rescue Projected global ▪ Significant health issue in the US with >107.000 deaths from in the US market (USD) size (USD) 1 annual growth 1 overdoses in 2021 ▪ Based on amorphOX® and designed to treat overdoses 1,100 10
Slide 12: OX640 – emergency treatment of allergic reactions
12 OX640 – emergency treatment of allergic reactions Rescue drug global Auto-injector market Projected global ▪ First line treatment today: intramuscular auto-injectors in the US market (USD) size (USD) annual growth ▪ OX640 offers clear differentiation 4,000 9 ▪ Needle free alternative based on amo
Slide 13: Sustainability
13 Sustainability
Slide 14: Orexo improves the lives of people
14 Orexo improves the lives of people Focus areas building a foundation for Orexo´s contribution to a more sustainable world
Slide 15: Financial & near time milestones
15 Financial & near time milestones
Slide 16: 2022 – building for future growth
16 2022 – building Group net revenues US Pharma net revenues for future 624 571 SEK M SEK M growth EBITDA US Pharma EBIT –115 308 SEK M SEK M FY EBITDA positive excluding external non-repeating costs related to: • MODIA® study • OX640 1st clinical study Cash position US Pharma EBIT margin • OX124 Hu
Slide 17: Potential milestones in near-term
17 Potential milestones in near-term ➢ ➢ ➢ ➢ ➢
Slide 18: For more information please visit www.orexo.com
18 For more information please visit www.orexo.com. You can also follow Orexo at Twitter @orexoabpubl, LinkedIn and YouTube. Headquarter Sweden, Orexo AB, P.O. Box 303, 751 05 Uppsala, Sweden, E-mail: info@orexo.com, Phone: +46 (0)18 780 88 00 Subsidiary US, Orexo US Inc. 150 Headquarters Plaza East